LYTIR

Company · LXRX

Lexicon Pharmaceuticals, Inc.

Name as listed on its exchange; filed with the SEC as LEXICON PHARMACEUTICALS, INC.

Nasdaq's symbol directory lists LXRX on Nasdaq as “Lexicon Pharmaceuticals, Inc. - Common Stock”.

In the 12 months to Nov 19, 2026: insiders bought on 1 occasion ($50K); 2 filings by holders of 5% or more.

All insider filings at the SEC

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Michael Exton, Chief Executive Officer bought on 1 day latest Nov 6, 2026 bought $50K
Every trade (1)
  1. BUYMichael Exton, Chief Executive Officer bought Nov 6, 2026 30,064 shares filing $50K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. FMR LLC filed Nov 5, 2026 Schedule 13G/A passive 66,743,389 shares filing 15%
  2. FMR LLC filed Aug 6, 2026 Schedule 13G/A passive 51,782,044 shares filing 11.7%

Sources: SEC EDGAR (Forms 4 and 144) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.